Metropolis Healthcare Limited (METROPOLIS) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.091x

Based on the latest financial reports, Metropolis Healthcare Limited (METROPOLIS) has a cash flow conversion efficiency ratio of 0.091x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs1.32 Billion ≈ $14.25 Million USD) by net assets (Rs14.43 Billion ≈ $156.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See METROPOLIS net asset quality index to measure how much of total assets are equity-financed.

Metropolis Healthcare Limited - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Metropolis Healthcare Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Metropolis Healthcare Limited's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Metropolis Healthcare Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Metropolis Healthcare Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Tiv Taam
TA:TTAM
0.162x
Perpetual Equity Investment Company Ltd
AU:PIC
-0.011x
Shoper S.A.
WAR:SHO
0.225x
Cre8 Direct Ningbo Co Ltd
SHE:300703
0.055x
Sophia Genetics SA
NASDAQ:SOPH
-0.145x
Ningbo Water Meter Co Ltd
SHG:603700
0.020x
Zoneco Group Co Ltd
SHE:002069
0.203x
Guangdong Liantai Environmental Protection Co Ltd
SHG:603797
0.040x

Annual Cash Flow Conversion Efficiency for Metropolis Healthcare Limited (2014–2025)

The table below shows the annual cash flow conversion efficiency of Metropolis Healthcare Limited from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see METROPOLIS company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs13.35 Billion
≈ $144.34 Million
Rs2.63 Billion
≈ $28.41 Million
0.197x -18.05%
2024-03-31 Rs10.99 Billion
≈ $118.88 Million
Rs2.64 Billion
≈ $28.56 Million
0.240x -3.68%
2023-03-31 Rs9.91 Billion
≈ $107.14 Million
Rs2.47 Billion
≈ $26.72 Million
0.249x -12.54%
2022-03-31 Rs8.88 Billion
≈ $96.05 Million
Rs2.53 Billion
≈ $27.39 Million
0.285x -18.92%
2021-03-31 Rs7.08 Billion
≈ $76.57 Million
Rs2.49 Billion
≈ $26.93 Million
0.352x -14.09%
2020-03-31 Rs5.25 Billion
≈ $56.79 Million
Rs2.15 Billion
≈ $23.25 Million
0.409x +90.72%
2019-03-31 Rs4.20 Billion
≈ $45.42 Million
Rs901.51 Million
≈ $9.75 Million
0.215x -11.37%
2018-03-31 Rs4.29 Billion
≈ $46.41 Million
Rs1.04 Billion
≈ $11.24 Million
0.242x -18.09%
2017-03-31 Rs3.44 Billion
≈ $37.22 Million
Rs1.02 Billion
≈ $11.00 Million
0.296x -4.95%
2016-03-31 Rs2.94 Billion
≈ $31.78 Million
Rs914.16 Million
≈ $9.89 Million
0.311x +72.03%
2015-03-31 Rs3.84 Billion
≈ $41.56 Million
Rs694.91 Million
≈ $7.52 Million
0.181x -25.29%
2014-03-31 Rs3.18 Billion
≈ $34.37 Million
Rs769.22 Million
≈ $8.32 Million
0.242x --

About Metropolis Healthcare Limited

NSE:METROPOLIS India Diagnostics & Research
Market Cap
$321.61 Million
Rs29.74 Billion INR
Market Cap Rank
#14275 Global
#731 in India
Share Price
Rs573.75
Change (1 day)
+5.22%
52-Week Range
Rs421.75 - Rs2236.70
All Time High
Rs3431.71
About

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinic… Read more